Compare NCSM & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCSM | MXCT |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.0M | 129.6M |
| IPO Year | 2017 | 2021 |
| Metric | NCSM | MXCT |
|---|---|---|
| Price | $55.99 | $1.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 26.7K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 239.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,471,000.00 | $33,026,000.00 |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $4.81 | $18.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.73 | $0.64 |
| 52 Week High | $87.36 | $2.40 |
| Indicator | NCSM | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 70.95 |
| Support Level | $35.60 | $0.72 |
| Resistance Level | $75.57 | $1.77 |
| Average True Range (ATR) | 1.91 | 0.10 |
| MACD | 1.70 | 0.02 |
| Stochastic Oscillator | 93.57 | 77.17 |
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completion, and field development strategies. The company provides its products and services to E&P companies for use in onshore and offshore wells, predominantly those drilled with horizontal laterals in unconventional and conventional oil and natural gas formations. It also provides tracer diagnostics services and sells products for well construction including casing buoyancy systems, liner hanger systems and toe initiation sleeves, along with certain complementary products from third parties. The company operates in the United States, Canada and other countries, with the majority of its revenue generated from Canada.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.